We invite you to read the following article on the importance of transparency in the costs of medicines and health products, which the WHO has made official through a resolution calling for greater transparency in the pharmaceutical sector, urging Member States to collaborate on this matter.
In the global healthcare scenario, transparency in drug costs emerges as a fundamental factor that benefits both consumers and patients. This transparency not only helps determine the fair price of a drug, but also enables physicians, patients and governments to make informed decisions, thus correcting information imbalances between buyers and sellers.
Open disclosure of costs helps level the playing field, allowing healthcare stakeholders to access accurate and detailed information. This is essential for informed policy debate, especially with regard to the allocation of appropriate incentives for drug research and development. By knowing the costs involved in creating new treatments, governments can set policies that encourage innovation without compromising equitable access to care.
In addition, cost transparency is a cornerstone for building public trust in democratic processes and accountability of both governments and pharmaceutical industries. When citizens can clearly see how public resources are spent and how drug prices are determined, it strengthens trust in institutions and promotes greater accountability in decision-making.
In a world where health care is essential to quality of life, transparency emerges as a powerful tool to promote equity and efficiency in the distribution of medical resources and treatments.
Read or DOWNLOAD the article:
Article resolution transparency WHO (1)
Access the Resolution:
A72_R8-sp
